Off-Label Drug Repurposing Research

AI-powered analysis of FDA-approved drugs being repurposed for novel indications — metformin, low-dose naltrexone, rapamycin, statins, and more. Leveraging existing safety profiles for new therapeutic hypotheses.

Key Mechanisms

• AMPK/mTOR pathway modulation (metformin)
• Opioid growth factor receptor agonism (LDN)
• mTOR inhibition and autophagy induction (rapamycin)
• Mevalonate pathway inhibition (statins)
• GCase enhancement (ambroxol)

Notable Compounds

• Metformin
• Low-dose Naltrexone (LDN)
• Rapamycin/Sirolimus
• Statins (atorvastatin)
• Ambroxol
• Dimethyl fumarate

Disease-Specific Research

• Off-Label Drug Repurposing Research for ALS (Amyotrophic Lateral Sclerosis)
• Off-Label Drug Repurposing Research for Stage IV Cancer
• Off-Label Drug Repurposing Research for Alzheimer's Disease
• Off-Label Drug Repurposing Research for Parkinson's Disease
• Off-Label Drug Repurposing Research for Autoimmune Diseases